IQVIA HoldingsFRA:QTS +0.39%90 Days Payable is 71.95 as of Mar. 2026, which is 183% above its 10-year median of 25.40. GuruFocus rates FRA:QTS with a GF Score™ of 90/100 and a GF Value™ of €218.53 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 63.16% on this metric.
The historical rank and industry rank for IQVIA Holdings's Days Payable or its related term are showing as below:
FRA:QTS'
s Days Payable Range Over the Past 10 Years
Min: 15.18 Med: 25.4 Max: 120.18
Current: 97.77
During the past 13 years, IQVIA Holdings's highest Days Payable was 120.18. The lowest was 15.18. And the median was 25.40.
FRA:QTS's Days Payable is ranked better than 63.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs FRA:QTS: 97.77
IQVIA Holdings's Days Payable
declined
from Mar. 2025 (77.85) to Mar. 2026 (71.95).
It may suggest that IQVIA Holdingsaccelerated paying its suppliers.
IQVIA Holdings Days Payable Related Terms
IQVIA Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:QTS vs WAT, ILMN, NTRA: Days Payable Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
IQVIA Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (FRA:QTS) has a Days Payable of 71.95 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IQVIA Holdings and its competitors. This is 183% above median its historical median of 25.40. Over the past decade, IQVIA Holdings' Days Payable has ranged from 15.18 to 120.18. According to the industry distribution chart, IQVIA Holdings ranks #70 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 36.8%.
Is IQVIA Holdings' Days Payable too high?
IQVIA Holdings' current Days Payable of 71.95 is 183% above median its 10-year median of 25.40. Over the past 10 years, this metric has ranged from a low of 15.18 to a high of 120.18. The Medical Diagnostics & Research industry median Days Payable is 67.28. IQVIA Holdings' value of 71.95 is 6.9% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #70 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Days Payable compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #70 out of 190 companies for Days Payable. This puts IQVIA Holdings in the upper half of its industry. The industry median Days Payable is 67.28. IQVIA Holdings' value of 71.95 is 6.9% above this benchmark. Historically, IQVIA Holdings' own Days Payable has ranged from 15.18 to 120.18 over the past decade. While the company's 10-year median is 25.40 vs. the industry median of 67.28, IQVIA Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current Days Payable of 71.95 is 6.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Days Payable is 71.95, which is 183% above median its own 10-year median of 25.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (FRA:QTS) is currently considered Modestly Undervalued. The stock's GF Value™ is €218.53, compared to a current price of €169.40 — trading 22.5% below its estimated fair value. The current Days Payable is 71.95, which is 183% above median its 10-year median of 25.40 and 6.9% above the Medical Diagnostics & Research industry median of 67.28. IQVIA Holdings' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For IQVIA Holdings (FRA:QTS), the current Days Payable is 71.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (FRA:QTS) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of €169.40 is trading 22.5% below its estimated GF Value™ of €218.53.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for FRA:QTS:
Days Payable: 71.95 (183% above median its 10-year median of 25.40)
GF Value™: €218.53 vs. price of €169.40 (22.5% below fair value)
Industry Position: 6.9% above the Medical Diagnostics & Research median (#70 of 190)
No single metric tells the full story. See the FRA:QTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
90GF Score
Get the complete analysis for FRA:QTS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QTS has been successfully added to your 
